Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 33Neoplasm Metastasis 5Breast Neoplasms 4Prostate Carcinoma Metastatic to the Bone 2Multiple Myeloma 2Metastatic Castration-resistant Prostate Cancer 2Hormone Refractory Prostate Cancer 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Prostate Cancer Metastatic to Bone 1Prostate Adenocarcinoma 1Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1Lymphatic Metastasis 1Lung Neoplasms 1Castrate-Resistant Prostate Cancer 1Bone Metastatic Castration-resistant Prostate Cancer 1Bone Metastases 1Bone Diseases 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Prednisone 2Docetaxel 2radium Ra 223 dichloride 1cabazitaxel 1atezolizumab 1Sodium Chloride 1OGX-011 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Castrate-Resistant Prostate Cancer × radium Ra 223 dichloride × Clear all
NCT02814669 2019-09-24

Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

Hoffmann-La Roche

Phase 1 Completed
45 enrolled
Genitourinary

Castrate-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡